Lexicon Pharmaceuticals (NASDAQ:LXRX) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 2.5 by 6 Brokerage Firm. 2 Wall Street Firms have rated the stock as a strong buys. 3 Brokerage Firms have advised hold. A sell rating was given by 1 analyst. Lexicon Pharmaceuticals (NASDAQ:LXRX) : On Thursday heightened volatility was witnessed in Lexicon Pharmaceuticals (NASDAQ:LXRX) which led to swings in the share price. The stock opened for trading at $11.13 and hit $12.09 on the upside , eventually ending the session at $11.68, with a gain of 4.85% or 0.54 points. The heightened volatility saw the trading volume jump to 967,643 shares. The 52-week high of the share price is $15.79 and the company has a market cap of $1,212 million. The 52-week low of the share price is at $6.299306 .
Lexicon Pharmaceuticals (NASDAQ:LXRX) stock has received a short term price target of $ 19.88 from 4 Analyst. The share price can be expected to fluctuate from the mean short term target, can be seen from the standard deviation reading of $8.07. The higher estimate of target price is $28 , while the lower price target estimate is $11
The stock has recorded a 20-day Moving Average of 13.1% and the 50-Day Moving Average is 15.14%.
Lexicon Pharmaceuticals, Inc. (Lexicon) is a biopharmaceutical company. The Company is focused on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Companys telotristat etiprate is an orally delivered small molecule drug candidate, as a treatment for carcinoid syndrome. It has completed two Phase II clinical trials and is conducting a single Phase III clinical trial of telotristat etiprate in carcinoid syndrome patients. The Companys sotagliflozin is an orally delivered small molecule drug candidate, as a treatment for type 1 and type 2 diabetes. The Company has completed two Phase II clinical trials of sotagliflozin in type 2 diabetes patients and an additional clinical trial of sotagliflozin in type 2 diabetes patients with renal impairment. It has also completed a Phase II clinical trial of sotagliflozin in type 1 diabetes patients.